GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

GSK plc GSK announced that it has signed an ... on the remaining three — Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps ...

Despite its profile as a long-acting IL-5 receptor antagonist with convenient semiannual dosing, GSK's depemokimab, the most advanced asthma pipeline asset, has generated relatively limited ...

While physician enthusiasm for depemokimab is more tempered compared to other pipeline agents, the therapy may still be well-positioned to meet critical needs in severe asthma management.